Cymbiotika, a wellness brand best known for its liquid vitamin pouches, released something on Monday. It is called the Liposomal Beauty Peptide Complex, twenty-six packets in a box for seventy-four dollars. If you missed the drop, you are not the target audience. If you already know what the word “liposomal” is doing in the product name, you are probably also the person who has been asking the question this piece is going to answer, which is: why is this word suddenly on every third launch, and what is it actually doing to the active ingredient inside?
The answer is nanocarriers. Nanocarriers are the delivery vehicles that most premium skincare launches now use to move ingredients across your stratum corneum with more efficiency than the ingredients could achieve on their own. The stratum corneum is the top forty-percent-of-a-hair-width layer of dead-cell brick-and-mortar that keeps everything in a cosmetic bottle sitting on your face rather than getting into your face. It is very good at its job. Nanocarriers are how the formulation industry gets around it. And unless you happen to read a lot of pharmaceutics journals in your spare time, you have almost certainly not been told which of your products contain them, at what particle size, in what concentration, or wrapped around what payload.
What a nanocarrier actually is
The most complete recent inventory is a review published in Pharmaceutics on January 3, 2026, out of the NMPA Key Laboratory for Research and Evaluation of Cosmetics at China Pharmaceutical University in Nanjing, with a co-corresponding author at RWTH Aachen in Germany. Yan, Zhang, Wu, Kang, Fu, Wang, Wang, Tang, and Wang. Twenty-plus pages. The kind of paper that no consumer magazine will ever cite because it looks too dry to be interesting, and which contains the most information you can find in one place about what has actually shipped into your bathroom over the last five years.
The taxonomy the paper lays out is straightforward once you accept that the entire category is fundamentally a materials science problem dressed up in skincare packaging. Nanocarriers are microscopic containers, particle sizes 10 to 1,000 nanometers, that hold an active ingredient inside a shell. The shell is designed to (a) protect the active from oxidation, hydrolysis, and light degradation while sitting in the bottle, (b) modify how the active moves through the outer skin layers, (c) release the active at a controlled rate once it gets where it is going, and often (d) enhance skin hydration on its own through the physics of forming an occlusive film on the surface. Different shell materials produce different classes of nanocarrier:
Vesicular nanocarriers are hollow spheres made of phospholipid bilayers, functionally similar to a cell membrane. Liposomes are the original. Transfersomes are more flexible versions that squeeze through skin more effectively. Ethosomes contain ethanol to fluidize the shell. Niosomes swap phospholipids for non-ionic surfactants, which is cheaper and more stable. All four can carry water-loving and oil-loving actives at the same time, which is unusual and useful.
Lipid-based nanocarriers use solid or semi-solid lipid cores rather than hollow vesicles. Solid lipid nanoparticles (SLNs) melt only above skin temperature, which gives them controlled release. Nanostructured lipid carriers (NLCs) mix solid and liquid lipids to fix the drug-loading capacity issue that pure SLNs have. Both form occlusive films on the skin surface that raise hydration mechanically, before any active has been released.
Emulsion-based nanocarriers are microemulsions and nanoemulsions — oil-in-water or water-in-oil emulsions with droplet sizes small enough (typically under 100 nm) to be optically transparent and physically stable in ways ordinary emulsions are not. These are the systems that scale easily, which is why they dominate commercial skincare. L’Oréal’s foundational patents on cosmetic nanoemulsion chemistry date to the late 1990s.
Polymeric nanocarriers use synthetic or natural polymers to build particles, micelles (self-assembled polymer spheres), and dendrimers (branched polymer trees). These are tunable in ways lipid systems are not — you can engineer specific release rates, stimuli-responsive triggers (pH, temperature, enzyme), and surface functionalization. They are also the class that requires the most careful biocompatibility work because synthetic polymers and their degradation products vary widely in dermal safety.
Inorganic nanoparticles include mesoporous silica for high-loading drug delivery, titanium dioxide and zinc oxide for physical sunscreens (already familiar to any consumer), and various metallic nanomaterials. These are where the safety questions get most pointed, because — unlike lipid or polymer systems — inorganics do not degrade in the body over any short timeframe.
Cyclodextrin inclusion complexes are not technically nanocarriers in the vesicle sense but are grouped alongside them. Cyclodextrins are ring-shaped sugar molecules with a hydrophobic pocket. Small poorly-soluble actives (retinol, essential oils, some peptides) slide into the pocket, gain solubility and stability, and lose irritation potential. Widely used and mostly boring, from a safety perspective.
Why the industry loves them
The efficacy story is the honest part. When you replace a standard retinol formula with a retinol nanoemulsion gel, you actually get four times more drug deposited into the dermis and roughly double the skin penetration — not a marginal upgrade, a step-change. This is Algahtani et al., cited in the Yan review, using the exact language: “more than 4-fold drug deposition rate and more than 2-fold skin penetration compared to RT emulsion and RT gel.” When a polymeric micelle carries oleanolic acid, skin roughness drops 0.673% at four weeks and 7.835% at eight weeks — measurable, if not enormous. When porcine placenta extract is encapsulated in polymeric nanoparticles, ROS generation in epidermal keratinocytes drops from 180.58 ± 9.15% to 89.90 ± 19.30%.
The reason this matters commercially is that most cosmetic actives are diva molecules. Retinol falls apart in light and air. Vitamin C oxidizes on contact with almost anything. EGCG is barely stable in water. Peptides degrade in the presence of skin enzymes. The traditional formulation options were: use unstable ingredients that lose efficacy by month three of the bottle’s life, use derivatives that are more stable but less potent (like magnesium ascorbyl phosphate instead of ascorbic acid), or over-formulate the active concentration and hope that enough survives. Nanocarriers solve this by hiding the active inside a shell that shields it from the outside world until the moment of release. This is why premium serum shelf life has quietly extended over the last decade. It is why brands can now claim potent retinol formulations that do not turn brown by week six. The delivery system, not the concentration on the label, is doing the work.
The second commercial win is what the paper calls “occlusive film formation.” Solid lipid nanoparticles and nanostructured lipid carriers form a thin film on the surface of the skin when applied. That film alone increases hydration — before any active in the formulation has done anything. So a product built on an NLC platform can legitimately claim a hydration benefit at the vehicle level, on top of whatever the active is doing. This is why some products feel richer and more moisturizing than their ingredient list would suggest.
The third and most understated win is that nanocarriers reduce irritation. Retinol wrapped in a liposome or cyclodextrin releases more slowly, at lower peak concentrations, and often bypasses the receptors on the surface keratinocytes that trigger the burning-and-flaking response. This is why sensitive-skin retinol formulations increasingly rely on encapsulated retinol or retinaldehyde — the tolerance profile improves without sacrificing the pharmacologic effect at the dermal level. BASF launched a retinol encapsulation ingredient called VitaGuard A in January 2025 specifically for this reason.
Why the safety literature is uncomfortable
Now the part the marketing does not mention. Yan et al. state, clean quote:
“Owing to their minute sizes and unique shapes, nanoparticles can easily cross membranes, entering cells, tissues, and organs, and cause cell damage. The chemical reactivities and biological activities are usually greater at the nanoscale size as compared to the larger particles. This can lead to the increased generation of ROS and free radicals, which can bring about inflammation and induce oxidative stress, resulting in damage to cell membranes, proteins, and DNA.”
The specific inorganic nanocarriers the review flags: ZnO and TiO2. Both are ubiquitous in mineral sunscreens as nanoparticles. Both, per the review, “can result in an increase in the production of cytokines and other pro-inflammatory mediators, thereby causing necrosis and allergies.” This is not a shocking claim — it has been in the toxicology literature since the mid-2000s — but the mainstream mineral-sunscreen consumer conversation has largely elided it in favor of the (also real) benefit of physical UV protection. The reality is that not-all-nanoparticles-are-the-same is not a marketing slogan; it is a genuine safety principle. A lipid-based nanocarrier that biodegrades in the skin over 24 hours has a different safety profile than a titanium dioxide nanoparticle that persists.
Emulsion-based nanocarriers have their own concern: they typically require high surfactant and cosurfactant concentrations to remain stable, and those concentrations can independently cause skin irritation. This is why some “fast-absorbing serums” sting despite otherwise benign ingredient lists. The delivery vehicle is the irritant, not the active. Polymeric systems require case-by-case biocompatibility work depending on the polymer, and the review is explicit that “biocompatibility and degradability of some synthetic polymers require careful assessment; potential toxicity of some materials or degradation products.”
The elephant in the room the review does not have data for is systemic absorption. Nanoparticles small enough to cross the stratum corneum are, by definition, also small enough to reach the vascularized dermis. From the dermis, some fraction can enter capillary circulation. The paper acknowledges this in general terms — nanoparticles can cross membranes, enter cells, tissues, and organs — but does not provide plasma concentration data, organ distribution data, or whole-body exposure numbers for cosmetic nanocarriers. This is the data that regulators everywhere are demanding, and that the cosmetic industry has been slow to generate. The microbiome question — what happens to skin microbiota when nanocarriers penetrate into the follicle and interact with resident bacteria — is almost completely unstudied at the level of commercial products.
The regulatory gap is the real story
The United States is the world’s largest cosmetic market and has, functionally, no cosmetic nanotechnology regulation. The 2007 FDA Nanotechnology Task Force recommendations were the first federal response. The 2011 “Guidance for Industry: Safety of Nanomaterials in Cosmetic Products” is still the operative document. Neither creates a mandatory pre-market notification, a mandatory labeling requirement, a mandatory particle-size disclosure, or a mandatory nano-specific safety data submission. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) — the largest reform of U.S. cosmetic law in eighty years — imposed facility registration, product listing, adverse-event reporting, and safety substantiation requirements. It did not impose nano-specific rules. A U.S. cosmetics company can put a titanium dioxide nanoparticle in a serum tomorrow and label it “titanium dioxide.” No consumer can distinguish it from bulk titanium dioxide on the label.
Europe is the opposite. Under Regulation (EC) No. 1223/2009, every cosmetic nanomaterial must undergo safety assessment based on intrinsic physicochemical properties, must be notified to the Commission at least six months before marketing, and must be listed on the ingredient label with the suffix “[nano]” — a labeling requirement most American consumers have never seen because it does not appear on U.S.-market versions of European products. Animal testing is prohibited outright for safety assessment, which forces the industry into ex vivo and in vitro immunotoxicity assays. The EU also maintains a running list of permitted, restricted, and prohibited nanomaterials in cosmetics, which is updated as the SCCS (Scientific Committee on Consumer Safety) issues opinions.
China’s National Medical Products Administration — which happens to be the institutional home of the Yan et al. review’s authors — has been developing its own framework aggressively over the last five years, though the paper itself does not describe those regulations in detail. The gap between what the paper knows and what it discloses about China’s regulatory approach is, in itself, informative about where the industry expects the next round of regulatory pressure to come from.
The Yan et al. summary of the global regulatory situation is direct: “There are remaining critical gaps in the regulatory landscape, including a lack of globally harmonized definitions, insufficient long-term safety data for many nanomaterials, and the absence of specific guidelines for novel and complex nanocarrier systems.” Translation: nobody, anywhere, has caught up.
What this means for how you shop
The word “liposomal” on a label is not a warning. It is not a red flag. In most cases it is a signal that the formulator has invested in a delivery system that will make the active more stable and more effective. Cymbiotika’s new peptide launch is likely, on balance, a legitimate technical improvement over a non-encapsulated peptide serum at a similar price. BASF’s VitaGuard A is a real ingredient with real data. Encapsulated retinol is genuinely more tolerable than free retinol. Nanoemulsions genuinely absorb faster. None of this is being made up.
What is being made up is the implication that these are undifferentiated categories. A liposome is not a solid lipid nanoparticle is not a mesoporous silica nanoparticle is not a titanium dioxide nanoparticle. The safety profile of each depends on the shell material, the payload, the particle size, the manufacturing process, and where in the skin the particle ends up. The label word “liposomal” or “encapsulated” tells you almost nothing about which of these actually apply.
Practical rules that survive the science:
Prefer lipid-based systems (liposomes, transfersomes, SLNs, NLCs, nanoemulsions) over inorganic systems for repeat daily use. Lipid nanocarriers biodegrade, integrate with the skin’s own lipid barrier, and do not persist. This is not a hard rule — ZnO and TiO2 in mineral sunscreens remain the safest broad-spectrum UV filters available, and their nanoparticle forms are what allow them to be cosmetically elegant — but for chronic non-sunscreen products, lipid vehicles have a stronger long-term safety story.
Be skeptical of “nanoemulsion” products that sting. The stinging is likely the surfactant load required to stabilize the nanoemulsion, not the active. This is a formulation quality issue, and it is not fixed by pushing through it.
Assume that every premium retinol, vitamin C, and peptide product in your rotation already uses some form of encapsulation. If it is well-formulated, this is invisible to you as a consumer. If it is badly formulated, it will be visibly unstable in the bottle (color change, phase separation, odor).
Read EU-market ingredient labels when you can find them. A product manufactured for the EU and marketed in the U.S. will not carry the “[nano]” suffix on the U.S. INCI label. The EU INCI label will. Reverse-checking the same brand’s EU version tells you what your U.S. label is hiding.
And accept that the FDA is going to update its 2011 guidance, at some point, under pressure that is currently building. The regulatory environment for cosmetic nanomaterials in the U.S. will look substantially different by the end of the decade. Consumer literacy needs to catch up first, because the industry will not lead this shift on its own.
The best delivery systems disappear into the product. That is the point of them. It is also why consumer transparency has to be forced — the industry has no commercial incentive to explain what you cannot see.